"Carcinosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
| Descriptor ID |
D002296
|
| MeSH Number(s) |
C04.557.435.290 C04.557.450.795.290
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carcinosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Carcinosarcoma".
This graph shows the total number of publications written about "Carcinosarcoma" by people in this website by year, and whether "Carcinosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinosarcoma" by people in Profiles.
-
Salivary Carcinosarcoma: An Extremely Rare and Highly Aggressive Malignancy. Laryngoscope. 2020 05; 130(5):E335-E339.
-
Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017 03 13; 31(3):411-423.
-
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
-
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
-
Role of TGF-ß signaling in uterine carcinosarcoma. Oncotarget. 2015 Jun 10; 6(16):14646-55.
-
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
-
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
-
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
-
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun 01; 28(16):2727-31.
-
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov; 107(2):177-85.